Cyxone takes next step in Multiple Sclerosis program engaging Contract Development & Manufacturing Organization for production of T20K

Cyxone (publ) announces today that the company has engaged a renowned European Contract Development & Manufacturing Organization (CDMO) for the scale-up and production of the active ingredient of its drug candidate T20K. The production will be performed in accordance with Good Manufacturing Practice (GMP), exploring a brand-new manufacturing method. The collaboration will initially cover method development and later supply material for use in non-clinical and clinical development activities.

Cyxone is developing T20K, a peptide aimed for the treatment of multiple sclerosis (MS). Preclinical data indicate that the drug candidate prevents disease progression in a model system and therefore shows potential to slow or prevent disease progression including preventing the demyelination which causes the symptoms of MS.

“We are pleased to have established a collaboration with one of Europe’s leading manufacturers of therapeutic peptides. T20K GMP manufacturing is an important step before non-clinical safety studies and future clinical studies. A feasibility study will be the first step of this collaboration permitting further optimization of the scale up process. The agreement represents our commitment to the T20K program and indicates that we are on schedule with our non-clinical plans,” comments Tara Heitner, CEO, Cyxone.

Tara Heitner, CEO
Tel: +46 70 781 88 08
Email: tara.heitner@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden

This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se. For more information, please visit www.cyxone.com